ATG-027 / Antengene - LARVOL DELTA

ATG-027, a first-in-class B7-H3/PD-L1 bispecific antibody, shows potent T cell activation capability and in vivo anti-tumor efficacy (SITC 2022) - "ATG-027 can also inhibit the interaction between PD1/PD-L1 to rescue T cell activity suppression. ATG-027’s dual T cell activation function and powerful ADCC, CDC, and ADCP properties contribute to its promising anti-tumor efficacy in preclinical models."

IO biomarker • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD276 • IFNG • IL2

Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced that it has presented posters from preclinical studies of four pipeline assets, ATG-031, ATG-101, ATG-018, and ATG-027 at the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)...In the poster, results were presented from in vitro studies to evaluate the immune function and in vivo studies to assess the anti-tumor efficacy of ATG-027 using mice bearing syngeneic colorectal cancer cells overexpressing human B7-H3. Results showed that ATG-027 binds to B7-H3 and PD-L1 expressing cells with high affinity. ATG-027 demonstrated higher ADCC and ADCP activity compared with anti-PD-L1 and anti-B7-H3 parental antibodies."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting (PRNewswire) - "At the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022), set to take place on November 8-12, 2022, in Boston....Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody. Three poster presentations showcase preclinical data of ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027, a B7H3/PD-L1 bispecific antibody discovered in-house."

Preclinical • Oncology

Antengene Announces Interim 2022 Financial Results and Provides Corporate Update (PRNewswire) - "Internal Discovery Program: (i) IND Candidates for the Remainder of 2022: ATG-022 (Claudin 18.2 antibody-drug conjugate). IND filing expected in 2H2022; (ii) 2023 Potential IND/CTA Filings: ATG-031 (anti-CD24 monoclonal antibody); (iii) Early Stage, IND Track Programs: ATG-027 (B7H3/PD-L1 bispecific antibody), ATG-032 (LILRB antibody) and ATG-041 (Axl-Mer inhibitor)."

IND • Oncology

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates (PRNewswire) - "Planning 2 INDs per Year (Antengene has global rights): (i) 2022 IND Candidates: Antengene plans to submit an IND application for ATG-018 (ATR inhibitor) in H1:22. In addition, preclinical studies are also underway to support IND/CTA applications of ATG-022 (Claudin 18.2 antibody-drug conjugate) in 2022; (ii) 2023 Potential IND/CTA Filings: ATG-031 (CD24 antibody) and ATG-027 (B7H3/PD-L1 bispecific antibody); (iii) Early Stage, IND Track Programs: ATG-032 (LILRB antibody) and ATG-041 (Axl-Mer inhibitor)."

IND • Preclinical • Oncology